Prevention Science

, Volume 11, Issue 2, pp 207–218 | Cite as

An Extended Model of Reasoned Action to Understand the Influence of Individual- and Network-Level Factors on African Americans’ Participation in HIV Vaccine Research

  • Paula M. FrewEmail author
  • Matthew Archibald
  • Dazon Dixon Diallo
  • Su-I Hou
  • Takeia Horton
  • Kayshin Chan
  • Mark J. Mulligan
  • Carlos del Rio


In the United States, the number and proportion of HIV/AIDS cases among black/African Americans continue to highlight the need for new biomedical prevention interventions, including an HIV vaccine, microbicide, or new antiretroviral (ARV) prevention strategies such as pre-exposure prophylaxis (PrEP) to complement existing condom usage, harm reduction methods, and behavioral change strategies to stem the HIV epidemic. Although black/African Americans are disproportionately impacted by HIV/AIDS, their participation in HIV clinical research continues to have unique challenges. We theorize that interaction among multilevel factors creates ideal alignment for minority participation in HIV clinical studies. Thus, we initially set out to test an extended model of reasoned action with 362 participants to understand the interplay of sociopsychological and network-level considerations influencing minority participation in HIV prevention research efforts. In this study, we linked the intrapersonal dimensions of attitudes, beliefs, and normative concerns to community-level components, appraisal of involvement with the clinical research organization, an entity which operates within a networked structure of community partner agencies, and identification with coalition advocacy aims. Various participatory outcomes were explored including involvement in future HIV vaccine community functions, participation in community promotion of HIV vaccine research, and community mobilization. Three-stage least squares estimates indicated similar findings across three models. Significant effects demonstrate the importance of positive attitudes toward HIV vaccine research, favorable health research beliefs, perceived social support for participation, HIV/AIDS issue engagement, and perceived relevance of the clinical research site’s mission and values. Identification of these nuanced pathway effects provides implications for tailored community program development.


HIV/AIDS HIV vaccine African Americans Community engagement Willingness to participate 



The authors wish to thank Hannah Cooper, ScD, Emory University and Emily Bass, AIDS Vaccine Advocacy Coalition (AVAC) for scientific and editorial review, the APRCC members for their support of this study, and our anonymous reviewers for excellent comments and suggestions.


  1. AIDS Vaccine Advocacy Coalition. (2008). Anticipating the results of PrEP trials: A powerful new HIV prevention tool may be on the horizon. Are we prepared? Retrieved September 24, 2008, from
  2. Ajzen, I. (1991). The theory of planned behavior. Organizational Behavior and Human Decision Processes, 50, 179–211.CrossRefGoogle Scholar
  3. Ajzen, I., & Fishbein, M. (1980). Understanding attitudes and predicting behavior. Englewood Cliffs, NJ: Prentice-Hall.Google Scholar
  4. Ajzen, I., & Madden, T. J. (1986). Prediction of goal-directed behavior: Attitudes, intentions, and perceived behavioral control. Journal of Experimental Social Psychology, 22, 453–474.CrossRefGoogle Scholar
  5. Albarracin, D., & Wyers, R. S. (2000). The cognitive impact of past behavior: Influences on beliefs, attitudes, and future behavioral decisions. Journal of Personality and Social Psychology, 79, 5–22.CrossRefPubMedGoogle Scholar
  6. Albarracin, D., Johnson, B. T., Fishbein, M., & Meullerleile, P. A. (2001). Theories of reasoned action and planned behavior as models of condom use: A meta-analysis. Psychological Bulletin, 127, 142–161.CrossRefPubMedGoogle Scholar
  7. Allen, M., Liang, T., Salvia, T., Tjugum, B., Gulakowski, R., & Murguia, M. (2005). Assessing the attitudes, knowledge, and awareness of HIV vaccine research among adults in the United States. Journal of Acquired Immune Deficiency Syndrome, 40, 617–624.CrossRefGoogle Scholar
  8. Bagozzi, R. P., Lee, K., & Van Loo, M. F. (2001). Decisions to donate bone marrow: The role of attitudes and subjective norms across cultures. Psychology & Health, 16, 29–56.CrossRefGoogle Scholar
  9. BeLue, R., Taylor-Richardson, K. D., Lin, J., Rivera, A. T., & Grandison, D. (2006). African Americans and participation in clinical trials: Differences in beliefs and attitudes by gender. Contemporary Clinical Trials, 27, 498–505.CrossRefPubMedGoogle Scholar
  10. Berkley, S. F., & Koff, W. C. (2007). Scientific and policy challenges to development of an AIDS vaccine. The Lancet, 370, 94–101.CrossRefGoogle Scholar
  11. Black AIDS Institute. (2008). Left behind: black America: A neglected priority in the global AIDS epidemic. Retrieved August 12, 2008, from
  12. Bollen, K. A. (1996). An alternative two stage least squares (2SLS) estimator for latent variable equations. Psychometrika, 61, 109–121.CrossRefGoogle Scholar
  13. Bollen, K. A. (2001). Two-stage least squares and latent variable models: Simultaneous estimation and robustness to misspecifications. In R. Cudeck, S. D. Toit, & D. Sorbom (Eds.), Structural equation modeling: Present and future. A Festschrift in Honor of Karl Joreskog (pp. 119–138). Lincoln, NC: Scientific Software.Google Scholar
  14. Brown, T. A. (2006). Confirmatory factor analysis for applied research (1st ed.). New York: Guilford.Google Scholar
  15. Brown-Peterside, P., Chiasson, M. A., Ren, L., & Koblin, B. A. (2000). Involving women in HIV vaccine efficacy trials: Lessons learned from a vaccine preparedness study in New York City. Journal of Urban Health, 77, 425–437.CrossRefPubMedGoogle Scholar
  16. Cargill, V. A., & Stone, V. E. (2005). HIV/AIDS: A minority health issue. Medical Clinics of North America, 89, 895–912.CrossRefPubMedGoogle Scholar
  17. Centers for Disease Control and Prevention. (2007a). HIV/AIDS surveillance report. Rev ed (Vol. 17, pp. 1–54). Atlanta, GA: US Department of Health and Human Services.Google Scholar
  18. Centers for Disease Control and Prevention. (2007b). Rapid HIV testing in outreach and other community settings—United States, 2004–2006. Morbidity and Mortality Weekly, 56, 1233–1237.Google Scholar
  19. Centers for Disease Control and Prevention. (2008). HIV/AIDS surveillance supplemental report: Cases of HIV infection and AIDS in the United States and dependent areas, by race/ethnicity, 2002–2006. Retrieved September 25, 2008, from
  20. Corbie-Smith, G., Thomas, S. B., Williams, M. V., & Moody-Ayers, S. (1999). Attitudes and beliefs of African Americans toward participation in medical research. Journal of General Internal Medicine, 14, 537–546.CrossRefPubMedGoogle Scholar
  21. Crosby, R. A., Holtgrave, D. R., Bryant, L., & Frew, P. M. (2004a). Correlates of negative intent to receive an AIDS vaccine: An exploratory study. International Journal of STDs & AIDS, 14, 552–557.CrossRefGoogle Scholar
  22. Crosby, R. A., Holtgrave, D. R., Bryant, L., & Frew, P. M. (2004b). Factors associated with the acceptance of an AIDS vaccine: An exploratory study. Preventive Medicine, 39, 804–808.CrossRefPubMedGoogle Scholar
  23. Curbow, B., Fogarty, L. A., McDonnell, K. A., Chill, J., & Scott, L. B. (2006). The role of physician characteristics in clinical trial acceptance: Testing pathways of influence. Journal of Health Communication, 11, 199–218.CrossRefPubMedGoogle Scholar
  24. Davis, C., & Randhawa, G. (2006). The influence of religion on organ donation and transplantation among the Black Caribbean and Black African population—a pilot study in the United Kingdom. Ethnicity & Disease, 16, 281–285.Google Scholar
  25. Djomand, G., Katzman, J., di Tommaso, D., Hudgens, M., Counts, G., Koblin, B., et al. (2005). Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002. Public Health Reports, 120, 543–548.PubMedGoogle Scholar
  26. Fauci, A., Johnston, M., Dieffenbach, C., Burton, D., Hammer, S., Hoxie, J., et al. (2008). HIV vaccine research: The way forward. Science, 321, 530–532.CrossRefPubMedGoogle Scholar
  27. Fishbein, M., & Ajzen, I. (1975). Belief, attitude, intention, and behavior. Menlo Park, CA: Addison-Wesley.Google Scholar
  28. Frew, P. M., Archibald, M., Martinez, N., del Rio, C., & Mulligan, M. (2008a). Promoting HIV vaccine research in the African American community: Does the theory of reasoned action explain potential outcomes of involvement? Challenge: The Journal of the Morehouse Research Institute, 13, 61–97.Google Scholar
  29. Frew, P. M., Crosby, R. A., Salazar, L. F., Gallinot, L., Bryant, L. O., & Holtgrave, D. R. (2008b). Acceptance of an HIV/AIDS vaccine among minority women. Journal of the National Medical Association, 100, 802–813.Google Scholar
  30. Frew, P. M., del Rio, C., Clifton, S., Archibald, M., Hormes, J., & Mulligan, M. J. (2008c). Factors influencing HIV vaccine community engagement in the urban South. Journal of Community Health, 33, 259–269.CrossRefGoogle Scholar
  31. Fuchs, J., Durham, M., McLellan-Lemal, E., Vittinghoff, E., Colfax, G., Gurwith, M., et al. (2007). Negative social impacts among volunteers in an HIV vaccine efficacy trial. Journal of Acquired Immune Deficiency Syndromes, 47, 1–7.Google Scholar
  32. Gagnon, M. P., & Godin, G. (2000). Young adults and HIV vaccine: Determinants of intention of getting immunized. Canadian Journal of Public Health, 91, 432–434.Google Scholar
  33. Gibbons, F. X. (2008). Health behavior constructs: Theory, measurement & research (Intention, Expectation, and Willingness). Retrieved January 16, 2009, from
  34. Gifford, A. L., Cunningham, W. E., Heslin, K. C., Andersen, R. M., Nakazono, T., Lieu, D. K., et al. (2002). Participation in research and access to experimental treatments by HIV-infected patients. New England Journal of Medicine, 346, 1373–1402.CrossRefPubMedGoogle Scholar
  35. Giocos, G., Kagee, A., & Swartz, L. (2007). Predicting hypothetical willingness to participate (WTP) in a future phase III HIV vaccine trial among high-risk adolescents. AIDS and Behavior, 11, 842–851.CrossRefGoogle Scholar
  36. Halpern, S. D., Metzger, D. S., Berlin, J. A., & Ubel, P. A. (2001). Who will enroll? Predicting participation in a phase II AIDS vaccine trial. Journal of Acquired Immune Deficiency Syndromes, 27, 281–288.PubMedGoogle Scholar
  37. HIV Prevention Trials Network. (2008). Community participation. Retrieved June 24, 2008, from
  38. Kkafaar, Z., Kagee, A., Lesch, A., & Swartz, L. (2007). Is participation in HIV vaccine trials a health promoting behaviour? AIDS Care, 19, 1307–1309.CrossRefGoogle Scholar
  39. Kline, R. B. (2005). Principles and practice of structural equation modeling (2nd ed.). New York: Guilford.Google Scholar
  40. Koblin, B., Holte, S., Lenderking, B., & Heagerty, P. (2000). Readiness for HIV vaccine trials: Changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. Journal of Acquired Immune Deficiency Syndromes, 24, 451–457.PubMedGoogle Scholar
  41. Koniak-Griffin, D., & Stein, J. A. (2006). Predictors of sexual risk behaviors among adolescent mothers in a human immunodeficiency virus prevention program. Journal of Adolescent Health, 38, 297. (e.291–211).PubMedGoogle Scholar
  42. Landovitz, R. (2007). Recent efforts in biomedical prevention of HIV. Topics in HIV Medicine, 15, 99–103.PubMedGoogle Scholar
  43. Leventhal, H., Brissette, I., & Leventhal, E. A. (2003). The common-sense model of self-regulation of health and illness. In L. D. Cameron & H. Leventhal (Eds.), The self-regulation of health and illness behaviour (pp. 42–65). London, UK: Routledge.Google Scholar
  44. Liu, A. Y., Grant, R. M., & Buchbinder, S. P. (2006). Preexposure prophylaxis for HIV: Unproven promise and potential pitfalls. Journal of the American Medical Association, 296, 863–865.CrossRefPubMedGoogle Scholar
  45. McCormack, S., Hayes, R., Lacey, C. J. N., & Johnson, A. M. (2001). Science, medicine, and the future: Microbicides in HIV prevention. British Medical Journal, 322, 410–413.CrossRefPubMedGoogle Scholar
  46. McKnight, P. E., McKnight, K. M., Sidani, S., & Figueredo, A. J. (2007). Missing data: A gentle introduction. New York: Guilford.Google Scholar
  47. Mclaws, M. L., Irwig, L. M., Oldenburg, B., Mock, P., & Ross, M. W. (1996). Predicting intentions to use condoms in homosexual men: An application and extension of the theory of reasoned action. Psychology & Health, 11, 745–755.CrossRefGoogle Scholar
  48. Meyers, L. S., Gamst, G., & Guarino, A. J. (2006). Applied multivariate research: Design and interpretation. Thousand Oaks, CA: Sage.Google Scholar
  49. Miedema, F. (2008). A brief history of HIV vaccine research: Stepping back to the drawing board? AIDS, 22, 1699–1703.CrossRefPubMedGoogle Scholar
  50. Moore, J., Klasse, P., Dolan, M., & Ahuja, S. (2008). AIDS/HIV. A STEP into darkness or light? Science, 320, 753–755.CrossRefPubMedGoogle Scholar
  51. Morrow, G., Hickok, J., & Burish, T. (1994). Behavioral aspects of clinical trials. An integrated framework from behavior theory. Cancer, 74, 2676–2682.CrossRefPubMedGoogle Scholar
  52. Muhib, F., Lin, L., Stueve, A., Miller, R., Ford, W., Johnson, W., et al. (2001). A venue-based method for sampling hard-to-reach populations. Public Health Reports, 116, 216–222.CrossRefPubMedGoogle Scholar
  53. National Medical Association. (2001). Recommendation of the clinical trials consensus panel. Journal of the National Medical Association, 92, 464–471.Google Scholar
  54. National Minority AIDS Council. (2008). AIDS crisis in communities of color prompts demand for national AIDS plan. Retrieved August 31, 2008, from
  55. Newman, P. A. (2006). Toward a science of community engagement. The Lancet, 367, 302.CrossRefGoogle Scholar
  56. Newman, P. A., Duan, N., Lee, S. J., Rudy, E. T., Seiden, D. S., Kakinami, L., et al. (2005). HIV vaccine acceptability among communities at risk: The impact of vaccine characteristics. Vaccine, 24, 2094–2101.CrossRefPubMedGoogle Scholar
  57. Newman, P. A., Duan, N., Roberts, K. J., Seiden, D. S., Rudy, E. T., Swendeman, D., et al. (2006). HIV vaccine trial participation among ethnic minority communities. Journal of Acquired Immune Deficiency Syndromes, 41, 210–217.CrossRefPubMedGoogle Scholar
  58. Peterson, J. L., Coates, T. J., Catania, J. A., Middleton, L., Hilliard, B., & Hearst, N. (1992). High-risk sexual behavior and condom use among gay and bisexual African-American men. American Journal of Public Health, 82, 1490–1494.CrossRefPubMedGoogle Scholar
  59. Porter, J. P., Glass, M. J., & Koff, W. C. (1989). Ethical considerations in AIDS vaccine testing. Review of Human Subjects Research, 11, 1–4.PubMedGoogle Scholar
  60. Potts, M. (1994). The urgent need for a vaginal microbicide in the prevention of HIV transmission. American Journal of Public Health, 84, 890–891.CrossRefPubMedGoogle Scholar
  61. Prejean, J., Song, R., An, Q., & Hall, H. (2008). Subpopulation estimates from the HIV incidence surveillance system—United States, 2006. Morbidity and Mortality Weekly, 57, 985–989.Google Scholar
  62. Priddy, F. H., Cheng, A. C., Salazar, L. F., & Frew, P. M. (2006). Racial and ethnic differences in knowledge and willingness to participate in HIV vaccine trials in an urban population in the Southeastern US. International Journal of STDs & AIDS, 17, 99–102.CrossRefGoogle Scholar
  63. Quinn, S. C. (2004). Ethics in public health research: Protecting human subjects: The role of community advisory boards. American Journal of Public Health, 94, 918–922.CrossRefPubMedGoogle Scholar
  64. Reeder, G. D., Davison, D. M., Gipson, K. I., & Hesson-McInnis, M. S. (2001). Identifying the motivations of African American volunteers working to prevent HIV/AIDS. AIDS Education and Prevention, 13, 343–354.CrossRefPubMedGoogle Scholar
  65. Roberts, K. J., Newman, P. A., Duan, N., & Rudy, E. T. (2005). HIV vaccine knowledge and beliefs among communities at elevated risk: Conspiracies, questions and confusion. Journal of the National Medical Association, 97, 1662–1671.PubMedGoogle Scholar
  66. Rossi, L. (2008). HIV prevention researchers to compare common ARV as a pill and vaginal gel in unique study: Getting inside the cells and minds of women: Trial looks at drug absorption and adherence of different formulations of tenofovir. Retrieved July 17, 2008, from
  67. Roth, P. L. (1994). Missing data—a conceptual review for applied psychologists. Personnel Psychology, 47, 537–560.CrossRefGoogle Scholar
  68. Salazar, L. F., Holtgrave, D. R., Crosby, R. A., Frew, P. M., & Peterson, J. L. (2005). Issues related to gay and bisexual men’s acceptance of a future AIDS vaccine. International Journal of STDs & AIDS, 16, 546–548.CrossRefGoogle Scholar
  69. Sanders, S. A., Graham, C. A., Yarber, W. L., Crosby, R. A., Dodge, B., & Milhausen, R. R. (2006). Women who put condoms on male partners: Correlates of condom application. American Journal of Health Behavior, 30, 460–466.PubMedGoogle Scholar
  70. Sheeran, P. (2002). Intention-behavior relations: A conceptual and empirical review. In W. Stroebe & M. Hewstone (Eds.), European review of social psychology (Vol. 12, pp. 1–36). Chichester, UK: Wiley.CrossRefGoogle Scholar
  71. Smith, Y. R., Johnson, A. M., Newman, L. A., Greene, A., Johnson, T. R. B., & Rogers, J. L. (2007). Perceptions of clinical research participation among African American women. Journal of Women’s Health, 16, 423–505.CrossRefPubMedGoogle Scholar
  72. Sneed, C. D., & Morisky, D. E. (1998). Applying the theory of reasoned action to condom use among sex workers. Social Behavior and Personality, 26, 317–327.CrossRefPubMedGoogle Scholar
  73. Southern States AIDS Directors Work Group. (2008). Southern states manifesto: Update 2008—HIV/AIDS and sexually transmitted diseases in the South. Retrieved September 25, 2008, from
  74. Strauss, R., Sengupta, S., Kegeles, S., McLellan, E., Metzger, D., & Eyre, S. (2001). Willingness to volunteer in future preventive HIV vaccine trials: Issues and perspectives from three US communities. Journal of Acquired Immune Deficiency Syndromes, 26, 63–71.PubMedGoogle Scholar
  75. Traylor, M. B., & Joseph, W. B. (1984). Measuring consumer involvement with products: Developing a general scale. Psychology & Marketing, 1, 65–77.CrossRefGoogle Scholar
  76. UNAIDS, & AIDS Vaccine Advocacy Coalition. (2007). Good participatory practice: Guidelines for biomedical HIV prevention trials. Geneva, Switzerland.Google Scholar
  77. Weiss, H. A., Halperin, D., Bailey, R. C., Hayes, R. J., Schmid, G., & Hankins, C. A. (2008). Male circumcision for HIV prevention: From evidence to action? AIDS, 22, 567–574.CrossRefPubMedGoogle Scholar
  78. Youle, M., & Wainberg, M. A. (2003). Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy. Journal of the International Associated Physicians in AIDS Care, 2, 102–105.CrossRefGoogle Scholar
  79. Zaichkowsky, J. L. (1985). Measuring the involvement construct. Journal of Consumer Research, 12, 341–352.CrossRefGoogle Scholar

Copyright information

© Society for Prevention Research 2009

Authors and Affiliations

  • Paula M. Frew
    • 1
    • 2
    • 3
    • 4
    Email author
  • Matthew Archibald
    • 5
  • Dazon Dixon Diallo
    • 6
  • Su-I Hou
    • 7
  • Takeia Horton
    • 1
    • 4
  • Kayshin Chan
    • 4
  • Mark J. Mulligan
    • 1
    • 2
    • 3
  • Carlos del Rio
    • 1
    • 2
    • 3
    • 8
  1. 1.Department of Medicine, Division of Infectious DiseasesEmory University School of MedicineAtlantaUSA
  2. 2.Emory Center for AIDS ResearchAtlantaUSA
  3. 3.The Hope Clinic of the Emory Vaccine CenterDecaturUSA
  4. 4.Rollins School of Public Health, Department of Behavioral Sciences and Health EducationEmory UniversityAtlantaUSA
  5. 5.Department of SociologyEmory UniversityAtlantaUSA
  6. 6.SisterLove, Inc.AtlantaUSA
  7. 7.College of Public Health, Department of Health Promotion and BehaviorUniversity of GeorgiaAtlantaUSA
  8. 8.Hubert Department of Global HealthRollins School of Public Health, Emory UniversityAtlantaUSA

Personalised recommendations